Man Group
SGMT icon

Man Group’s Sagimet Biosciences SGMT Stock Holding History

Man Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Sell
13,856
-39,921
-74% -$271K ﹤0.01% 2300
2026
Q1 		$281K Buy
53,777
+18,171
+51% +$101K ﹤0.01% 2227
2025
Q4 		$211K Sell
35,606
-11,340
-24% -$81.5K ﹤0.01% 2114
2025
Q3 		$322K Buy
+46,946
New +$381K ﹤0.01% 1978
2025
Q1 		– Sell
-17,322
Closed -$77.9K – 2346
2024
Q4 		$77.9K Buy
17,322
+992
+6% +$5.03K ﹤0.01% 1935
2024
Q3 		$45.2K Buy
+16,330
New +$50.3K ﹤0.01% 1923

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Man Group's SGMT Position: Q2 2026 in Review

Man Group reduced its Sagimet Biosciences (SGMT) stake by 74% in Q2 2026, selling an estimated $271K and leaving 13,856 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

Man Group first reported a position in SGMT in Q3 2024 and has held it in 6 quarters since. The position peaked at $322K in Q3 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Man Group held 13,856 shares of Sagimet Biosciences worth $107K as of Q2 2026.
  • Man Group sold 39,921 Sagimet Biosciences shares in Q2 2026, an estimated $271K.
  • Sagimet Biosciences made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2300 holding.
  • Man Group first reported a position in Sagimet Biosciences in Q3 2024 and has held it in 6 quarters since.
  • Man Group's Sagimet Biosciences position peaked at $322K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.